Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study

被引：0
|
作者：
Meredith Hoog
Juan M. Maldonado
Ruth Wangia-Dixon
Rachel Halpern
Erin Buysman
Garrett W. Gremel
Ahong Huang
Manige Konig
机构：
[1] Eli Lilly and Company,
[2] Lilly Corporate Center,undefined
[3] Eli Lilly Export S.A.,undefined
[4] Optum Inc.,undefined
[5] Tigermed-BDM,undefined
来源：
Diabetes Therapy | 2024年 / 15卷
关键词：
Dulaglutide; Glycated hemoglobin; Glucagon-like peptide-1 receptor; Hispanic/Latino; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：855 / 867
页数：12
相关论文
共 50 条
  • [1] Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study
    Hoog, Meredith
    Maldonado, Juan M.
    Wangia-Dixon, Ruth
    Halpern, Rachel
    Buysman, Erin
    Gremel, Garrett W.
    Huang, Ahong
    Konig, Manige
    DIABETES THERAPY, 2024, 15 (04) : 855 - 867
  • [2] Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study
    Hoog, Meredith
    Paczkowski, Rosirene
    Huang, Ahong
    Halpern, Rachel
    Buysman, Erin
    Stackland, Sydnie
    Zhang, Yiran
    Wangia-Dixon, Ruth
    DIABETES THERAPY, 2023, 14 (11) : 1947 - 1958
  • [3] Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study
    Meredith Hoog
    Rosirene Paczkowski
    Ahong Huang
    Rachel Halpern
    Erin Buysman
    Sydnie Stackland
    Yiran Zhang
    Ruth Wangia-Dixon
    Diabetes Therapy, 2023, 14 : 1947 - 1958
  • [4] Real-world comparative outcomes study in US patients with type 2 diabetes initiating basal insulin analogues
    Davis, K. L.
    Meyers, J. L.
    Tangirala, M.
    Wei, W.
    DIABETOLOGIA, 2012, 55 : S384 - S384
  • [5] Clinical and economic outcomes among injection-naive patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
    Mody, Reema
    Huang, Qing
    Yu, Maria
    Patel, Hiren
    Zhang, Xian
    Wang, Liya
    Grabner, Michael
    BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
  • [6] Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
    Lawrence Blonde
    Luigi Meneghini
    Xuejun Victor Peng
    Anders Boss
    Kyu Rhee
    Alka Shaunik
    Supriya Kumar
    Sidhartha Balodi
    Claire Brulle-Wohlhueter
    Rory J. McCrimmon
    Diabetes Therapy, 2018, 9 : 1347 - 1358
  • [7] Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
    Blonde, Lawrence
    Meneghini, Luigi
    Peng, Xuejun Victor
    Boss, Anders
    Rhee, Kyu
    Shaunik, Alka
    Kumar, Supriya
    Balodi, Sidhartha
    Brulle-Wohlhueter, Claire
    McCrimmon, Rory J.
    DIABETES THERAPY, 2018, 9 (03) : 1347 - 1358
  • [8] Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy
    Davis, Keith L.
    Tangirala, Muralikrishna
    Meyers, Juliana L.
    Wei, Wenhui
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (09) : 1083 - 1091
  • [9] Real-World Outcomes of Initiating Injectable Therapy With Insulin Glargine or Liraglutide Among Patients With Type 2 Diabetes
    Levin, Philip
    Wei, Wenhui
    Vlajnic, Aleksandra
    Pan, Chunshen
    Xie, Lin
    Lin, Jay
    Baser, Onur
    DIABETES, 2012, 61 : A4 - A4
  • [10] Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment
    Mody, Reema
    Grabner, Michael
    Yu, Maria
    Turner, Ralph
    Kwan, Anita Y. M.
    York, Whitney
    Lando, Laura Fernandez
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 995 - 1003
12345